摘要
目的使用拉米夫定治疗乙型肝炎表面抗原(HBeAg)阳性慢性乙型肝炎患者,观察治疗前和治疗中HBeAg水平对血清HBeAg转阴率的影响,分析血清乙肝病毒E抗原水平对拉米夫定疗效的预测作用。方法入选HBeAg阳性慢性乙型肝炎患者261例,根据治疗前血清HBeAg水平分为3组,A组204例,HBeAg水平≥1.0;B组31例,1.0>HBeAg水平≥0.1;C组26例,HBeAg水平<0.1。给予拉米夫定治疗1年后观察各组HBeAg血清转阴率。A组患者治疗12周后,根据HBeAg水平是否<1.0分为两组,观察两组患者治疗1年后HBeAg血清转阴率。结果 HBeAg阳性慢性乙型肝炎患者,拉米夫定治疗前血清HBeAg水平越低,治疗1年后HBeAg血清转阴率越高。拉米夫定治疗12周后,血清HBeAg水平降至1.0以下的患者血清HBeAg转阴率较高。结论拉米夫定治疗前和治疗12周HBeAg水平可预测HBeAg血清转阴率,HBeAg水平可作为抗病毒治疗对象的选择和疗效判断的指标。
Objective To study the relationships between serum HBeAg levels and lamivudine therapy efficacy in patients with chronic hepatitis B.Methods 261 patients with chronic hepatitis B were divided into 3 groups According to serum HBeAg levels.Group A： 204 cases,HBeAg levels≥1.Group B： 31 cases,1HBeAg levels≥0.1.Group C： 26 cases,HBeAg levels0.1.Patients were treated with lamivudine.Patients in Group A were divided into 2 groups according to serum HBeAg levels（HBeAg levels≥1 and HBeAg levels 1） after 12 weeks treatment.HBeAg negative rates were calculated in one year.Results The lower the HBeAg levels,the higher HBeAg negative rates in patients treated with lamivudine after one year.In Group A patients whose HBeAg level went down below 1 after 12 weeks treatment had higher HBeAg negative rates after one year.Conclusion HBeAg levels can predict HBeAg negative rates in patients with chronic hepatitis B treated with lamivudine.
出处
《实用临床医药杂志》
CAS
2011年第9期108-109,共2页
Journal of Clinical Medicine in Practice
